Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TOGETHER-Toronto: A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter, Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19

NCT04967430 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT04967430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04967430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TOGETHER-Toronto: A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter, Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
Lead sponsor
University Health Network, Toronto
Phase
Phase 3
Overall status
Unknown status
Start date
August 27, 2021
Completion date
June 30, 2022
Enrollment
763 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, sars-cov2